糖尿病肾病 中国就医指南

Diabetic nephropathy (DN) is a progressive microvascular complication of diabetes mellitus and the leading cause of end-stage kidney disease (ESKD) worldwide. It is defined by persistent albuminuria (urinary albumin-to-creatinine ratio ≥30 mg/g on two of three specimens collected within 3–6 months), declining glomerular filtration rate (GFR), and characteristic histopathological changes—including glomerular basement membrane thickening, mesangial expansion, and nodular glomerulosclerosis (Kimmelstiel-Wilson lesions). Pathogenesis involves a complex interplay of metabolic, hemodynamic, inflammatory, and fibrotic mechanisms: chronic hyperglycemia triggers advanced glycation end-product (AGE) formation, oxidative stress, activation of protein kinase C (PKC) and renin-angiotensin-aldosterone system (RAAS), podocyte injury, and endothelial dysfunction—culminating in glomerular hypertrophy, capillary leakage, and irreversible tubulointerstitial fibrosis. Epidemiologically, DN affects approximately 20–40% of individuals with type 1 or type 2 diabetes over their lifetime; prevalence rises with diabetes duration, age, and suboptimal glycemic control. In China, where over 141 million adults live with diabetes (IDF 2021), DN accounts for ~35% of incident ESKD cases—making it a critical public health priority. Key modifiable risk factors include poor glycemic control (HbA1c >7%), uncontrolled hypertension (especially systolic BP >140 mmHg), dyslipidemia, smoking, obesity, and recurrent urinary tract infections; non-modifiable risks include longer diabetes duration (>10 years), male sex, genetic predisposition (e.g., APOL1 variants in high-risk populations), and early-onset diabetes. Diabetic nephropathy profoundly impacts quality of life: patients experience fatigue, sleep disturbances, depression, sexual dysfunction, dietary restrictions, frequent clinic visits, and progressive physical limitations. As kidney function declines, anemia, bone-mineral disorders, fluid overload, and cardiovascular comorbidities intensify—contributing to markedly increased all-cause mortality. Early detection via annual urine albumin screening and eGFR monitoring is essential; once established, DN requires lifelong multidisciplinary management focused on slowing progression—not reversal—with strict blood pressure targets (<130/80 mmHg), RAAS inhibition (ACEi or ARB), SGLT2 inhibitors (proven renal and cardiovascular benefits), GLP-1 receptor agonists, lipid management, smoking cessation, and nutritional counseling. In advanced stages, patients transition to renal replacement therapy (dialysis or transplantation), which further burdens psychosocial well-being and economic resources.

# 糖尿病肾病治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：eGFR ≥60 mL/min/1.73m²，UACR <300 mg/g（早期DKD）

• •基础管理：血糖监测（HbA1c、空腹/餐后血糖）、血压控制（ACEI/ARB类）、低蛋白饮食指导

• •药物治疗（按疗程3个月计）：

- 优化档（原研+SGLT2i）：达格列净+替米沙坦+GLP-1RA，药费4,200–6,500元

二、介入/核心治疗方案

适用人群：eGFR 15–59 mL/min/1.73m²，进展性蛋白尿或难控高血压

• •肾动脉交感神经消融术（RDN）（三甲医院开展中）：

- 手术费+耗材（国产导管系统）：38,000–52,000元；进口系统：65,000–88,000元

三、晚期及复杂并发症方案

适用人群：eGFR <15 mL/min/1.73m²、透析依赖或合并心衰/严重贫血

• •维持性血液透析（每周3次）：医保报销后自付约1,200–2,000元/月
• •肾移植评估+等待期管理（含HLA配型、感染筛查等）：首年综合费用（不含移植手术）约28,000–45,000元

四、方案快速选择指南

• •预算≤3,000元/年：优选基础药物+生活方式干预（UACR<30mg/g者）
• •预算1万–5万元/年：推荐SGLT2i+RAS抑制剂联合，加定期肾功能动态监测
• •晚期/透析需求：优先纳入国家慢病门诊统筹，同步启动透析通路建立（自付约4,500–6,000元）